CRDF

Cardiff Oncology Inc. Common Stock (CRDF)

Stock · NASDAQ · Health Care

$0.9275as of 10/16/2026

Price chart

Open in TradingView

Active signals

High Beta27.5%
200 SMA Touch0.0%
Resistance level
$1.25
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

CRDF Signal Track Record

How signals performed across all stocks →

What CRDF's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike36-4.4%33%
Bollinger Band Breakout26-4.4%35%
Bollinger Band Breakdown20-2.6%40%
200-Day Moving Average TouchActive now12-4.0%17%
Any 20-session window (baseline)-0.9%48%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreati…

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Employees
30

Fundamentals

1-day range
$0.89$0.9949
Market cap
$74.71M
P/E (trailing)
—
P/E (forward)
-1.68
EPS (trailing)
$-0.59
Dividend yield
—
Beta
1.48
Avg. volume
773.1K
Dividend pay date
February 20, 2019
52-week range
$0.7566$3.31
Next earnings: November 12, 2026 · EPS estimate $-0.13After Closeconfirmed

How Cardiff Oncology Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$593.0KSG&A$14.22M (2399%)CRDF

Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub

Operating Income-$48.96M(-8256%)

Forecasts

7 analyst ratings

Buy 58%
Hold 42%
Sell 0%
1-year price forecast
High
$12
+1193.8%
Median
$6
+546.9%
Low
$1.2
+29.4%

Cardiff Oncology Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • CRDF
    Cardiff Oncology Inc. Common Stock
    $0.9
    ▼ 7.22%
    Market cap $74.71MP/E —
    $0.7566$3.31
  • ATRA
    Atara Biotherapeutics Inc. Common Stock
    $9.18
    ▼ 4.87%
    Market cap $74.33MP/E —
    $3.92$19.15
  • LONA
    LeonaBio Inc. Common Stock
    $5.2
    ▼ 1.70%
    Market cap $73.36MP/E —
    $2.21$14.21
  • CSBR
    Champions Oncology Inc. Common Stock
    $4.7
    ▼ 1.88%
    Market cap $72.11MP/E —
    $4.59$8.31
  • ELOX
    Eloxx Pharmaceuticals Inc. Common Stock
    $13.03
    ▼ 4.89%
    Market cap $71.48MP/E —
    $0$23.4
  • IMA
    ImageneBio Inc. Common Stock
    $4.04
    ▲ 0.25%
    Market cap $63.50MP/E —
    $3.9$9.1
  • GNTA
    Genenta Science S.p.A. American Depositary Shares
    $0.675
    ▲ 0.90%
    Market cap $63.16MP/E —
    $0.55$10

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
1.68M
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
24.21M
Total value held
$38.79M
Institutional holders
111
Top holders this quarter
  • Unknown3.98M
  • Unknown2.86M
  • Unknown2.65M
  • Unknown2.41M
  • Unknown1.76M
  • Unknown1.60M
  • Unknown1.21M
  • Unknown1.19M
  • Unknown922.4K
  • Unknown595.1K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.